Treatment withdrawal · people with epilepsy and depression
Sertraline showed no clear difference in withdrawals compared with cognitive behavioural therapy (moderate certainty).
1 finding from 1 review
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Quality of life (QOLIE‐89) (1‐ to 3‐month periods) · people with epilepsy and depression
1 finding from 1 review
Adverse effects · people with epilepsy and depression
1 finding from 1 review
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
Intervention not reported
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
88 participants
Very low
Intervention not reported
Withdrawals · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
88 participants
Low
Intervention not reported
Cognitive functioning · people with epilepsy and depression
1 finding from 1 review
Intervention not reported
Quality of life · people with epilepsy and depression
1 finding from 1 review
Intervention not reported
Adverse effects · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
88 participants
Low
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
RR 0.44 [0.05, 3.85]
15 participants
Very low
Treatment withdrawal · people with epilepsy and depression
Paroxetine showed no clear difference in withdrawals compared with doxepin (moderate certainty).
1 finding from 1 review
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Quality of life · people with epilepsy and depression
1 finding from 1 review
Adverse effects · people with epilepsy and depression
1 finding from 1 review
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults (aged 18 years+) with depression in bipolar disorder
Ketamine may leads to higher efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (low certainty).
1 finding from 1 review